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Angiogenesis, the process by which new blood vessels are formed from preexisting vasculature, is critical for
vascular remodeling during development and contributes to the pathogenesis of diseases such as cancer. Prior
studies from our laboratory demonstrate that the EphA2 receptor tyrosine kinase is a key regulator of
angiogenesis in vivo. The EphA receptor-mediated angiogenic response is dependent on activation of Rho
family GTPase Rac1 and is regulated by phosphatidylinositol 3-kinase. Here we report the identification of
Vav2 and Vav3 as guanine nucleotide exchange factors (GEFs) that link the EphA2 receptor to Rho family
GTPase activation and angiogenesis. Ephrin-A1 stimulation recruits the binding of Vav proteins to the
activated EphA2 receptor. The induced association of EphA receptor and Vav proteins modulates the activity
of Vav GEFs, leading to activation of Rac1 GTPase. Overexpression of either Vav2 or Vav3 in primary
microvascular endothelial cells promotes Rac1 activation, cell migration, and assembly in response to
ephrin-A1 stimulation. Conversely, loss of Vav2 and Vav3 GEFs inhibits Rac1 activation and ephrin-A1-
induced angiogenic responses both in vitro and in vivo. In addition, embryonic fibroblasts derived from
Vav2/ Vav3/ mice fail to spread on an ephrin-A1-coated surface and exhibit a significant decrease in the
formation of ephrin-A1-induced lamellipodia and filopodia. These findings suggest that Vav GEFs serve as a
molecular link between EphA2 receptors and the actin cytoskeleton and provide an important mechanism for
EphA2-mediated angiogenesis.
Angiogenesis, the process by which new blood vessels are
formed from preexisting vasculature, is critical for vascular
remodeling during development and contributes to the patho-
genesis of diseases such as cancer. Two critical steps in this
process are endothelial cell migration and assembly into new
tubules. Over the last decade, a diverse array of molecular
regulators that participate in the process of angiogenesis has
been identified (4, 47). The Eph family of receptor tyrosine
kinases is one such family of angiogenic regulators that plays a
prominent role in endothelial cell assembly and migration.
The Eph receptors belong to the largest family of receptor
tyrosine kinases in the genome, with 16 receptors and 9 ligands
identified to date in vertebrates (28, 38). Based on binding
specificity and structural properties, the Eph receptors are
divided into two subclasses, class A and class B (23). In gen-
eral, EphA receptors bind to glycosylphosphatidylinositol-
linked ephrin-A ligands, while EphB receptors bind to trans-
membrane ephrin-B ligands. Gene targeting studies have
established several class B Eph family members as key regu-
lators of embryonic vascular development (2, 24, 46). In con-
trast, class A Eph receptors have been shown to regulate post-
natal angiogenesis in adults. Ephrin-A1 stimulates endothelial
cell migration and assembly in culture (15, 34) and induces
corneal angiogenesis in vivo (37). More recently, Eph recep-
tors have been detected in tumor blood vessel endothelial cells
(reviewed in references 8 and 9). Inhibition of class A Eph
receptor signaling by soluble EphA2-Fc or EphA3-Fc recep-
tors decreased tumor volume, tumor angiogenesis, and meta-
static progression in vivo (6, 13, 18). A main target of soluble
EphA receptors appears to be EphA2, as EphA2-deficient
endothelial cells fail to migrate and assemble in vitro (7), and
loss of EphA2 receptor resulted in impaired tumor growth and
metastasis in vivo (10). These data support the crucial role for
Eph receptor-mediated regulation of angiogenesis.
Investigation of ephrin/Eph receptor-mediated signal trans-
duction mechanisms that regulate cellular responses in various
cell types has been centered on Rho-family GTPases (33). In
vascular smooth muscle cells, for example, the EphA4 receptor
stimulates RhoA activity via direct interaction with Vsm-Rho-
GEF (35), while ephrin-A1 stimulation inhibits Rac1 and p21-
activated kinase (PAK) activity (17). In endothelial cells, how-
ever, EphA2 receptor-mediated cell migration is dependent on
Rac1 GTPase activation (7). Ephrin-A1 stimulation induces
activation of the Rac1 GTPase, and a dominant negative N17
Rac1 mutant inhibits ephrin-A1-induced endothelial cell mo-
tility. Rac1 activity also appears to be regulated by phosphatidyl-
inositol 3 kinase (PI3K). PI3K-specific inhibitors, wortmannin,
LY294002, or a dominant negative p85 subunit of PI3K, block
ephrin-A1-induced Rac1 activation and endothelial cell migra-
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tion. These data suggest that the EphA2 receptor controls
endothelial cell motility by regulating Rac1 GTPase activity.
The molecular mechanism by which the EphA2 receptor
regulates the activity of Rac1 GTPase in endothelial cells re-
mains to be elucidated. The Vav family of guanine nucleotide
exchange factors (GEFs), which includes Vav1, Vav2, and
Vav3, has been shown to modulate activity of Rho, Rac, and/or
Cdc42 to elicit changes in cytoskeletal organization (27, 41,
48). In addition, Vav proteins can interact with the PI3K lipid
product phosphatidylinositol–3,4,5-triphosphate in activation
of Rac1 (16, 26). While the majority of studies on these pro-
teins have focused on functions in the immune system (45),
Vav2 and Vav3 display a broader tissue expression profile and
therefore likely regulate cytoskeletal dynamics in other cells
types (27). Vav2 and Vav3 are expressed in heart and other
highly vascularized organs, including placenta, lung, and kid-
ney (44, 48). As EphA2-mediated Rac1 activation in endothe-
lial cells is PI3K-dependent (7), these data suggest that Vav
proteins may link the EphA2 receptor to Rac1 directly and/or
through PI3K.
Through a yeast two-hybrid screen, we identified the Vav3
GEF as a binding partner of EphA2. In this study, we report
that both Vav3 and Vav2 GEFs are recruited to phosphory-
lated EphA2 receptors in mammalian cells. Endothelial cells
deficient in both Vav2 and Vav3 exhibit impaired activation of
Rac1 GTPase and endothelial cell migration and assembly in
response to ephrin-A1 ligand. In addition, loss of both Vav2
and Vav3 inhibits ephrin-A1-induced angiogenesis in vivo. We
propose that regulation of Rac1 GTPase signaling by modula-
tion of Vav2/3 activity may underlie endothelial responses to
ephrin-A1.
MATERIALS AND METHODS
Yeast two-hybrid screening. The mouse EphA2 cytoplasmic domain was
cloned into pBridge-LexA (BD Biosciences) (pSGS2) as a bait to screen a human
placenta library consisting of 3.5  106 independent clones (Clontech). Briefly,
yeast strain L40 [MATa his3200 trp1–901 leu2–3,112 ade2 LYS2::(lexAop)4-HIS3
URA3::(lexAop)8-lacZ GAL4] was transformed with pSGS2 and the placenta
cDNA library. The resulting transformants were screened for histidine protot-
rophy and expression of LacZ. The His LacZ clones that did not interact with
lamin C were subjected to PCR and restriction analyses to eliminate duplicate
clones. Among 14 unique His LacZ clones, two overlapping clones encom-
passing the SH2-SH3 domains of the Vav3 gene were identified.
Antibodies. Antibodies used for immunoblotting include the following: anti-
myc (1:1,000; BD Biosciences); anti-EphA2 (1:2,500) and phosphotyrosine an-
tibodies (1:600; Santa Cruz Biotechnology); anti--galactosidase (1:500; Chemi-
con); anti-tubulin (1:1,000; Sigma-Aldrich); anti-Rac1 and anti-cdc42 antibodies
(1:1,000 and 1:500, respectively; BD Bioscience); and anti-Vav3 (1:3,000; Up-
state Biotechnology). A mixture of polyclonal anti-EphA2 (0.5 g; C-20; Santa
Cruz Biotechnology) and monoclonal anti-EphA2 (1 g; D7; Upstate Biotech-
nology) antibodies were used to immunoprecipitate EphA2 from endothelial cell
lysates. Anti-Vav2 antibodies have been previously described (14).
In vitro binding assay. MBP-EphA2, the fusion of the intracellular portion of
mouse EphA2 and maltose-binding protein (MBP), was expressed in pMAL-c2X
(New England Biolabs) and purified on amylose resin according to the manu-
facturer’s instructions. Escherichia coli lysate containing glutathione S-trans-
ferase (GST)-Vav3 SH3-SH2-SH3 domains was incubated with amylose-bound
MBP-EphA2. After extensive washing, bound proteins were eluted and subjected
to Western blot analyses using anti-EphA2 and anti-Vav3 antibodies.
Coimmunoprecipitation and Western blot analyses. COS7 cells were cotrans-
fected with 1 g each of T7-tagged Vav2 or myc-tagged Vav3 and EphA2 per
well in a six-well dish using Lipofectamine 2000. Cells were lysed in Brij buffer
(10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 2 mM EDTA, 0.88% Brij, 0.125%
NP-40 plus protease inhibitors). T7-agarose (20 l of beads/ml of lysate; Nova-
gen) or Myc-agarose (20 l of beads/ml of lysate; Sigma-Aldrich) was used to
immunoprecipitate Vav2 or Vav3, respectively. The resulting proteins were re-
solved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and subjected to Western blotting using anti-EphA2. A mixture of
anti-EphA2 antibodies (D7 at 1:1,000 and sc-924 at 1:500) was also used in
immunoprecipitation, and precipitated proteins were subjected to SDS-PAGE
and Western blot analysis by Vav2 or Vav3 antibodies.
Fibroblast morphology assays. A total of 100,000 wild-type or Vav2/
Vav3/ embryonic fibroblasts were plated on glass slides precoated with ephrin-
A1, immunoglobulin G (IgG), or fibronectin by placing 1 ml/per well (six-well
dish) of the protein solution at 10 g/ml in the dish overnight and subsequently
blocking in Dulbecco’s modified Eagle’s medium containing 2% bovine serum
albumin for 30 min. Five hours after plating, cells were fixed in 4% paraformal-
dehyde, permeabilized in 0.4% Triton X-100, and stained with fluorescein iso-
thiocyanate-conjugated phalloidin to detect F-actin. Experiments were repeated
three times, and an average of 100 cells were examined and quantified for each
experiment.
Guanine nucleotide exchange assays. For Rac1 and cdc42 activation assays,
cells were serum starved for 24 h in OptiMEM, followed by stimulation with
ephrin-A1 (1 g ml1). Lysates were prepared and incubated with PAK1 p21-
binding domain (PBD)-GST beads (Upstate Biotechnology) as described by the
manufacturer’s protocol to pull down GTP-bound Rac1 and/or cdc42. Activated
Rac1 and cdc42 (or total Rac1 and cdc42 in lysates) were detected by immuno-
blotting using anti-Rac1 or anti-cdc42 antibodies (BD Transduction Labs). Rel-
ative levels of GTP-bound Rac1 and cdc42 were quantified by densitometry using
Scion Image 1.62c software analysis.
Endothelial cells. Primary murine pulmonary microvascular endothelial cells
(MPMEC) were isolated from 1- to 3-month-old wild-type or Vav2/Vav3 dual-
deficient mice (14) and maintained in EGM-2 medium (Clonetics), as previously
described (7, 39). Endothelial cell purity was greater than 95% in these cultures,
as determined by expression of CD31, an endothelial cell marker (data not
shown). For transfection experiments, primary bovine pulmonary microvascular
endothelial cells (BPMEC) were seeded into six-well plates and transfected with
1 g of plasmid DNA per well using Lipofectamine 2000 (Invitrogen) according
to the manufacturer’s instructions.
Migration assay. Migration assays using 6.5-mm, 8-m-pore-size Transwells
(Costar) were performed as described previously (7). Both sides of the transwell
were coated with a 1/20 dilution of growth factor-reduced Matrigel and blocked
with 1% bovine serum albumin. After 24 h of starvation in OptiMEM, cells
(100,000/well) were seeded into the upper chamber of transwells in the presence
or absence of ephrin-A1 (2.5 g ml1) in the lower chamber. After 5 h, cells on
the lower surface were fixed, stained with crystal violet, and counted in three
random fields from each well, with triplicate samples per condition.
Assembly assay. In vitro vascular assembly assays were performed as described
previously (7). Briefly, 12-well plates were coated with 100 l of growth factor-
reduced Matrigel (Becton-Dickinson). After 24 h of starvation in OptiMEM,
25,000 MPMEC were plated in wells in the presence or absence of ephrin-A1
(1.5 g ml1; R&D Systems) and photodocumented after 9 h. Images were
acquired on an Olympus CK40 inverted microscope through an Optronics DEI-
750C charge-coupled-device video camera using Scion Image capture software,
version 1.62c. Degree of assembly was quantified by measuring branch length,
i.e., the distance from branching point to the tip of assembled cells. Only assem-
bled cells consisting of at least three cells were measured. The branch length in
assembled endothelial cell networks was expressed as arbitrary units per field (at
a magnification of 10) in four random fields from each well, with triplicate
samples per condition, using Scion Image 1.62c software for analysis.
In vivo angiogenesis assay. Sponge assays for angiogenesis were performed as
described previously (7). Briefly, gel foam sponges (Pharmacia and Upjohn) were
cut into small pieces (2.5 to 3 mm wide by 5 mm long) and soaked with 100 l
of phosphate-buffered saline containing 10 g of ephrin-A1 or IgG. The sponges
were then implanted into the subcutaneous dorsal flank of recipient mice. Each
recipient received one ephrin-A1-treated sponge and one control IgG sponge
implanted in the opposite flank. After 7 days, the mice were injected with a 2%
tetramethyl rhodamine isothiocyanate (TRITC)–dextran–phosphate-buffered sa-
line solution to label host blood vessels (6), and the sponges were collected and
analyzed. Whole-mount images were acquired on an Olympus CK40 inverted
microscope through an Optronics DEI-750C charge-coupled-device video cam-
era using Scion Image, capture software version 1.62c. Density of blood vessels
within the sponges was quantified by fluorescence intensity of rhodamine-dextran
using Scion Image software. The density of fluorescent pixels within each field
(magnification, 10) was determined and compared in Vav2/ Vav3/ mice
with that in wild-type controls. Data are a representation of results from five
independent sponges in each genotype. Statistical significance was determined by
a two-tailed, paired Student’s t test.
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RESULTS
Activated EphA2 receptor recruits Vav2 and Vav3 GEFs. To
identify EphA2-interacting proteins that function to regulate
endothelial cell migration, we performed a yeast two-hybrid
screen. The bait construct consisted of the intracellular portion
of mouse EphA2 fused to the DNA binding domain of LexA.
Upon screening a cDNA library from human placenta, we
obtained two independent but overlapping interacting clones
that encoded the Vav3 GEF. To verify the interaction between
EphA2 and Vav3, the SH3-SH2-SH3 portion of Vav3 was
expressed as a GST fusion, and the EphA2 cytoplasmic domain
was expressed as an MBP fusion. Soluble GST-Vav3 was in-
cubated with MBP-EphA2 that was linked to amylose beads.
After extensive washing, only GST-Vav3 and MBP-EphA2
were eluted from the column (Fig. 1A). While MBP-EphA2
was phosphorylated and bound to GST-Vav3, MBP alone
failed to interact with GST-Vav3 (Fig. 1B), suggesting that the
binding is specific to EphA2 in vitro.
The observation that Vav3 interacted with the cytoplasmic
domain of EphA2 in yeast and in vitro raised the possibility
that Vav3 and EphA2 interact in mammalian cells. To test this
possibility, we transfected COS7 cells with a myc-tagged Vav3
and immunoprecipitated cell lysates with Myc-conjugated aga-
rose beads. As shown in Fig. 1C, the EphA2 protein was
readily detected in anti-Myc immunoprecipitates when the
cells were stimulated with ephrin-A1 but not in unstimulated
cells. The coimmunoprecipitation of EphA2 with the anti-Myc
antibody was dependent on the expression of Vav3 and was
undetectable in immunoprecipitates in which a control vector
was expressed. In addition, GST-Vav3 but not control GST
could also bind to endogenously expressed EphA2 in response
to ephrin-A1 ligand stimulation (Fig. 1D). These findings in-
FIG. 1. Interaction between EphA2 and Vav proteins. (A) The MBP-EphA2 cytoplasmic domain fusion protein and the GST-Vav3 SH3-SH2-
SH3 domain fusion protein were expressed in E. coli. Soluble GST-Vav3 was added to the MBP-EphA2-amylose column, and bound proteins were
eluted and analyzed by SDS-PAGE, followed by silver staining. (B) Western blot of eluted fractions as described in panel A and from control resin
with MBP alone. (C) EphA2 and myc-tagged Vav3 or vectors alone were cotransfected into COS7 cells. Cells were stimulated with ephrin-A1 at
indicated times, and cell lysates were immunoprecipitated with anti-myc-conjugated resin, followed by Western blot analysis with anti-EphA2
antibodies. Blots were stripped and reprobed for expression of Vav3. (D) A431 cell lysates were added to GST-Vav3 or control GST resin, and
bound proteins were eluted and analyzed by Western blot analysis using anti-EphA2 antibodies. (E and F) T7-tagged Vav2 or vector was
transfected into COS7 cells and stimulated in the presence or absence of ephrin-A1 for 5 min. Lysates were immunoprecipitated by anti-EphA2
(F) or anti-T7 (E), followed by Western blot analyses with anti-Vav2 (F) or anti-EphA2 (E). IP, immunoprecipitation; IB, immunoblotting.
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dicate that Vav3 and EphA2 interact when they are coex-
pressed in mammalian cells and that this interaction is depen-
dent on activation of the EphA2 receptor by ephrin-A1 ligand.
As Vav2 and Vav3 exchange factors are closely related and
both are broadly expressed in many tissue types, we investi-
gated whether Vav2 GEF also binds to EphA2 receptor. A
T7-tagged Vav2 GEF or control vector was transfected into
COS7 cells. Cells were stimulated in the presence or absence
of ephrin-A1 ligand. As shown in Fig. 1E, T7-conjugated beads
efficiently pulled down phosphorylated EphA2 in Vav2-trans-
fected cells but not in control vector-transfected cells. In the
reverse direction, Vav2 was readily detected in anti-EphA2
immunoprecipitates from cells transfected with Vav2 but not in
cells harboring control vector (Fig. 1F). Although Vav2 ap-
peared to bind to EphA2 in both stimulated and nonstimulated
cells, the intensity of the Vav2 band was stronger in cells
stimulated with ephrin-A1 ligand, suggesting that more Vav2
was recruited to the activated EphA2 receptor. Taken to-
gether, these results demonstrate that phosphorylated EphA2
receptor can bind to Vav2 or Vav3 GEFs in mammalian cells.
Mapping of interaction domains between EphA2 and Vav3.
To identify the domains within Vav3 that mediate the interac-
tion with the EphA2 receptor, a panel of Vav3 deletion mutant
constructs was generated and tested in the yeast two-hybrid
system for their interaction with EphA2 (Fig. 2A). Since the
original yeast two-hybrid-interacting clones of Vav3 contained
both SH2 and SH3 domains, we expressed the C-terminal SH2
or SH3 domain or the N-terminal portion (containing calponin
homology, GEF, pleckstrin homology [PH], and C1 domains)
of Vav3 and tested which domain(s) was sufficient to maintain
the interaction with EphA2 in the yeast two-hybrid assay. Nei-
ther the N-terminal portion (containing calponin homology,
GEF, PH, and C1 domains) nor the C-terminal SH3 domain of
Vav3 was able to bind to EphA2. In contrast, the SH2 domain
alone was sufficient to mediate an interaction with EphA2.
These data suggest that the SH2 domain of the Vav3 GEF
binds to phosphorylated tyrosine residue(s) on the EphA2
receptor.
We next sought to determine the Vav3 binding site on the
EphA2 receptor. To narrow the search, we began with a panel
of EphA2 deletion mutants (Fig. 2B). Deletion of the kinase
domain or a kinase-dead point mutation (D738N) (21) com-
pletely eliminated the ability to bind to Vav3, suggesting that
EphA2 kinase activity was essential for recruitment of Vav3.
This result, together with the data shown in Fig. 2A, indicated
a phosphorylated tyrosine as the binding site for Vav3. To
determine whether Vav3 binds to the two tyrosine residues in
the juxtamembrane (JM) domain, we examined Vav3 binding
to EphA2 mutants carrying a deletion of the JM domain or
bearing a double Y-to-F point mutation, Y587F/Y593F (FF).
Interestingly, deleting the JM did not affect binding in yeast,
but the FF mutation completely abolished binding to Vav3.
The failure of Vav3 to interact with the FF mutant could
suggest a possible direct interaction with the phosphorylated
JM tyrosines; however, the FF mutation also leads to a loss of
kinase activity (5, 49, 50). To determine whether Vav3 can
interact with the JM tyrosines or if loss of binding results from
a loss of kinase activity, we tested an EphA2 mutant (Y587E/
Y593E) that retains normal tyrosine kinase activity but cannot
be phosphorylated at the JM tyrosines (50). As shown in Fig.
FIG. 2. Domain mapping between EphA2 and Vav3. (A) The
EphA2 cytoplasmic domain was coexpressed in the yeast two-hybrid
assay with wild-type or various deletion mutants of Vav3. NT, not
tested. (B) The SH3-SH2-SH3 region of Vav3 was coexpressed in the
yeast two-hybrid assay with wild-type or various mutants of the EphA2
cytoplasmic domain. D738N is a kinase-dead mutation. (C) Analysis of
the Vav3 and wild-type or mutant EphA2 interaction by coimmuno-
precipitation. Vav3 and either wild-type or mutant constructs were
transfected into COS7 cells. Cell lysates were immunoprecipitated with
anti-myc-conjugated resin, followed by Western blot analysis using
anti-EphA2 antibodies. SAM Y/F, Y-to-F mutations in the SAM do-
main; FF, a double Y-to-F mutation (Y587F/Y593F). EE, a double
mutation of Y to E (Y587E/Y593E); juxt, juxtamembrane domain;
WT, wild type; CH, calponin homology domain.
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FIG. 3. Characterization of Vav GEF activity in Vav2/ Vav3/ MEFs. Wild-type or Vav2/ Vav3/ MEFs were plated on fibronectin-,
IgG-, or ephrin-A1-coated surfaces. (A) Wild-type cells were completely attached to an ephrin-A1-coated surface 45 min after plating, while
Vav2/ Vav3/ cells were still rounded. (B) Cells were stained with fluorescein isothiocyanate-phalloidin to detect F-actin 5 h after plating. Cells
with phenotypes of membrane ruffle, microspike, ruffle and microspike, or branched were shown and quantified in panel C. Experiments were
repeated three times, and an average of 100 cells were examined each time. *, P  0.05; **, P  0.01. (D) Active GTP-bound forms of Rac1 and
Cdc42 were analyzed by PAK1 PBD pull-down assay followed by immunoblotting in lysates from wild-type or Vav2/ Vav3/ MEFs stimulated
with ephrin-A1. Total Rac1 and Cdc42 levels within the lysate prior to PBD pull-down were detected by immunoblotting. WT, wild type; KO,
knockout.
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2B and C, the double mutation of Y to E significantly inhibited
binding to Vav3, suggesting that Vav3 may directly interact
with the phosphorylated tyrosines in the JM.
In addition to the two tyrosines in the JM domain, the
other region of EphA2 that appeared to affect Vav3 binding
was the sterile alpha motif (SAM) domain. Deletion of the
SAM domain significantly reduced binding to Vav3 (Fig.
2B). To test if phosphorylated tyrosines in the SAM can
serve as binding sites, we analyzed the ability of Vav3 to
bind to three mutations of Y to F (Y921F, Y929F, and
Y959F) in the EphA2 SAM (Fig. 2C). As shown in Fig. 2C,
a mutation of Y to F in any of these three tyrosine residues
moderately inhibited binding to Vav3, suggesting that the
SAM domain provides additional binding sites for Vav3.
Regulation of EphA2-dependent Rac1 activation by Vav
GEFs. Having established that Vav2/Vav3 and EphA2 interact
in a phosphorylation-dependent manner, we sought to deter-
mine whether the activated EphA2 receptor regulated Rho
family GTPases via Vav GEFs. As a first step, we examined the
ability of EphA receptors to regulate the activities of Vav2
and Vav3 in primary murine embryonic fibroblasts (MEFs).
Since MEFs do not express Vav1, they provide a suitable
background to analyze Vav2 and Vav3 activities specifically.
Wild-type or Vav2/ Vav3/ MEFs were plated on ephrin-
A1-, IgG-, or fibronectin-coated surfaces. Both wild-type and
Vav2/ Vav3/ MEFs attached and spread on a fibronectin-
coated surface, while none of them spread on an IgG-coated
surface after 45 min of plating (data not shown). In contrast,
when the wild-type or Vav2/ Vav3/ MEFs were plated
onto ephrin-A1-coated surfaces, both adhered, but only the
wild-type cells exhibited a spreading phenotype (Fig. 3A).
We also observed the effects of Vav deficiency on the mor-
phology of fibroblasts to assess the distinct morphological
changes elicited by RhoA, Cdc42, and Rac1. Specifically,
RhoA induces stress fiber formation, Cdc42 induces filopodia
extensions (a microspike phenotype), and Rac1 induces lamel-
lipodia formation and membrane ruffling (25). There was no
significant stress fiber formation in either wild-type or Vav2/
Vav3/ MEFs at 5 h postplating. Ephrin-A1 induced the
formation of membrane ruffles, microspikes, and a combina-
tion of both in approximately 70% of wild-type cells. In con-
trast, ruffles and microspikes were significantly reduced in
Vav2/ Vav3/ MEFs (Fig. 3B and C). The majority of
Vav2/ Vav3/ MEFs exhibited a “branched” phenotype in
which cells adhered but did not spread. No morphological
differences between wild-type and Vav2/ Vav3/ MEFs
were observed when they were plated on IgG- or fibronectin-
coated surfaces (Fig. 3C). Furthermore, ephrin-A1 stimulation
activated both Rac1 and Cdc42 GTPases in wild-type MEFs,
whereas GTP-bound Rac1 and Cdc42 levels were reduced
in ephrin-A1-stimulated Vav2/ Vav3/ MEFs (Fig. 3D).
Taken together, these data suggest that ephrin-A1 activates
Rac1 and Cdc42 GTPases through Vav2 and/or Vav3.
To directly test the activation state of Rac1 GTPase in en-
dothelial cells, we employed the PBD pull-down assay in cells
stimulated with ephrin-A1 or Fc control. Vav2 or Vav3 was
overexpressed in BPMEC. Cells were stimulated with ephrin-
A1, and activated GTP-bound Rac was isolated from lysates by
precipitation with PAK1 PBD-GST fusion proteins. As shown
in Fig. 4A, consistent with our previous findings (7), ephrin-A1
induced Rac1 activation in mock-transfected cells. Vav2- and
Vav3-transfected cells exhibited elevated basal levels of Rac
activation, and Rac activity was moderately increased in re-
sponse to ephrin-A1 stimulation. To determine whether en-
dogenous Vav2 and Vav3 are required for ephrin-A1-induced
activation of Rac1 in endothelial cells, we used primary micro-
vascular endothelial cells isolated from either Vav2/
Vav3/ mice or wild-type control mice. Endothelial cells iso-
lated from Vav2/ Vav3/ mice expressed no detectable
FIG. 4. Regulation of ephrin-A1-induced Rac1 activation by Vav
GEFs in endothelial cells. (A) Active GTP-bound Rac1 was analyzed
by PAK1 PBD pull-down assay using lysates from ephrin-A1-stimu-
lated BPMEC transfected either with vector, Vav2, or Vav3, expres-
sion constructs (top). Total Rac1 levels within the lysate prior to PBD
pull-down were detected by immunoblotting. Results were quantified
using Scion Image software and expressed as means  standard devi-
ations of six independent experiments (bottom). (B) Loss of Vav2 and
Vav3 expression in Vav2/ Vav3/ endothelial cells was confirmed
by Western blot analysis (left). EphA2 expression and phosphorylation
were not affected in Vav2/ Vav3/ cells, as judged by immunopre-
cipitation and Western blot analysis (right). (C) Active GTP-bound
forms of Rac1 were analyzed by PAK1 PBD pull-down assay followed
by immunoblotting using lysates from wild-type or Vav2/ Vav3/
MPMEC stimulated with ephrin-A1 (top). Total Rac1 within the ly-
sates prior to PBD pull-down was detected by immunoblotting. Results
were quantified using Scion Image software and expressed as means 
standard deviations of four independent experiments (bottom). WT,
wild type.
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FIG. 5. Overexpression of Vav2 and Vav3 promotes ephrin-A1-induced endothelial cell assembly and migration. (A) BPMEC were transfected
with Vav2, Vav3, or vector and assayed for their ability to assemble into capillary-like structures on growth factor-reduced Matrigel in response
to ephrin-A1. Phase-contrast view of BPMEC transfected with Vav2, Vav3, or vector 9 h after plating on Matrigel. Lower magnification view shows
that an equal number of cells was plated. (B) Immunofluorescence shows that transfected cells are incorporated into cellular networks, as judged
by anti-T7 (Vav2) or anti-Myc (Vav3) staining. (C) Quantification of the results shown in panel A. Branch length in assembled endothelial cell
networks was measured. Four fields per culture were quantified for each condition and experiments were repeated four times. (D) Migration of
BPMEC transfected with Vav2 or Vav3 in response to ephrin-A1 was quantified by transwell assay. The number of endothelial cells that had
migrated to the lower surface of the transwell in 5 h was counted. Three fields per transwell were quantified for each condition in triplicate samples,
and data are means  standard deviations of three independent experiments. GFP, green fluorescent protein.
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Vav2 or Vav3 proteins, but EphA2 expression and phosphor-
ylation were not affected in these mice (Fig. 4B). Ephrin-A1
stimulation induced elevation of Rac1-GTP levels at 2.5 and 5
min in wild-type endothelial cells, but this induction of Rac1
activity was impaired in Vav2/ Vav3/ cells (Fig. 4C).
Taken together, these results indicate that both Vav2 and Vav3
are activated by EphA receptor forward signaling to promote
Rac1 GTPase activity.
Vav family GEFs mediate ephrin-A1-induced endothelial
cell migration and assembly. As ephrin-A/EphA forward sig-
naling induces the activation of Rac1 GTPase via Vav2 and/or
Vav3 exchange factors and as EphAs are known to be critical
for adult angiogenesis (7), we investigated whether Vav pro-
teins might also be necessary for ephrin-A1-induced angio-
genic responses. We first assessed vascular assembly responses
in BPMEC transiently transfected with Vav2 or Vav3. As
shown in Fig. 5A, consistent with our previous findings (7),
ephrin-A1 induced vascular assembly in mock-transfected
cells. In Vav2- or Vav3-transfected cells, basal levels of assem-
bly were increased, and endothelial cell assembly into capil-
lary-like structures was significantly increased in response to
ephrin-A1 stimulation (Fig. 5A and C). Vav2- or Vav3-trans-
fected cells were incorporated into endothelial cellular net-
works, as judged by anti-T7 (Vav2) or anti-Myc (Vav3),
whereas green fluorescent protein-transfected control cells re-
mained isolated in the dish (Fig. 5B). Furthermore, ephrin-A1-
induced endothelial cell migration is significantly increased in
BPMEC transfected with either Vav2 or Vav3, compared to
mock-transfected cells (Fig. 5D). These data suggest a func-
tional link between Vav family GEFs and ephrin-A1-mediated
vascular endothelial cell migration and assembly.
To assess whether endogenous Vav2 and Vav3 are required
for endothelial cell assembly and migration, we performed
migration and assembly assays in MPMEC that are deficient in
both Vav2 and Vav3 proteins. Cultured wild-type and Vav2/
Vav3/ endothelial cells displayed similar morphology and
growth rates (data not shown). When stimulated with ephrin-A1
ligand, migration of Vav2/ Vav3/ MPMEC was signifi-
cantly impaired relative to wild-type control cells (Fig. 6A).
However, the migration response to serum was not affected in
Vav2/ Vav3/ MPMEC (Fig. 6A), indicating that the phe-
notype in these cells was not due to generalized migration
defects. When these cells were placed on Matrigel, endothelial
cell assembly into capillary-like structures was significantly in-
hibited in Vav2/ Vav3/ MPMEC compared to wild-type
control cells (Fig. 6B and C). Taken together, these data indi-
cate that Vav family GEFs are necessary for ephrin-A1-medi-
ated angiogenic responses.
Impaired ephrin-A1-induced angiogenesis in Vav2/
Vav3/ mice. Based on the defects in assembly and migration
of Vav2/ Vav3/ endothelial cells ex vivo, we wished to
determine if Vav2/ Vav3/ mice display impaired angio-
genesis in vivo. To test this, we implanted surgical sponges
impregnated with control IgG or ephrin-A1 subcutaneously
into the dorsal flank of Vav2/ Vav3/ mice or wild-type
controls. After 7 days, we injected the mice intravenously with
a TRITC-dextran solution to visualize host blood vessels asso-
ciated with sponges. In wild-type control mice, we observed a
marked increase in surface vessels associated with ephrin-A1-
treated sponges relative to control IgG sponges (Fig. 7A). In
contrast, Vav2/ Vav3/ mice showed a significant reduc-
tion in vascular density in response to ephrin-A1-treated
sponges (Fig. 7A and B). Though host vessels were observed in
the skin surrounding IgG-treated sponges, no infiltration of
these vessels into the control sponges was detected (data not
shown). These data suggest that Vav2/3 GEFs are required for
ephrin-A1-mediated angiogenic remodeling in vivo.
DISCUSSION
Vav GEFs link Eph receptors to Rho family GTPase activa-
tion. Investigation of ephrin/Eph receptor-mediated signal
transduction mechanisms that regulate cellular responses in
various cell types has been centered on Rho-family GTPases.
We have recently shown that EphA2 receptor-dependent en-
dothelial cell migration and assembly require the activation of
Rac1 GTPase (7). However, the mechanisms responsible for
EphA2 receptor-mediated Rac1 GTPase activation remain un-
defined. In this study, we show that when ephrins bind to Ephs,
a Rho family GEF, Vav2 or Vav3, is recruited to the EphA2
receptor, leading to increased Rac1 activity in both primary
endothelial cells and embryonic fibroblasts. In addition, we
observed that ephrin-A1-induced activation of Rac1 is im-
paired in Vav2/ Vav3/ endothelial cells and MEFs, im-
plicating Vav proteins as critical Rho family GEFs downstream
of Eph receptors.
FIG. 5—Continued.
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FIG. 6. Impaired cell migration and assembly in Vav2/ Vav3/ endothelial cells. (A) Migration of MPMEC derived from wild-type or
Vav2/ Vav3/ mice in response to ephrin-A1 or serum was quantified by transwell assay. The number of endothelial cells that had migrated
to the lower surface of the transwell in 5 h was counted. Three fields per transwell were quantified for each condition in triplicate samples, and
data are means  standard deviations of three independent experiments. (B) MPMEC isolated from wild-type or Vav2/ Vav3/ mice were
plated on a thin layer of growth factor-reduced Matrigel in the presence or absence of ephrin-A1 to examine and quantify vascular assembly. After
9 h, the endothelial cells were photographed. (C) Branch length in assembled endothelial cell networks was measured. Four fields per culture were
quantified for each condition, and experiments were repeated three times. KO, knockout.
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Our findings indicate that Vav2 and/or Vav3 are required for
ephrin-A1-induced endothelial cell migration/assembly and
Rac1 activation. It remains unclear whether ephrin-A1 stimu-
lation of Vav proteins leads to a direct activation of Rac1 or
whether ephrin-A1-induced Rac1 activation occurs indirectly
via the Vav-dependent activation of another GEF pathway.
Although Vav2/3 can function directly as exchange factors (1,
32, 42), it is interesting that Vav proteins contain multiple
SH2/SH3 adaptor motifs that may mediate the recruitment of
other Rac- or cdc42-specific GEFs to the activated Eph recep-
tor, as observed in the immune system (W. Swat et al., unpub-
lished observation). In the future, it will be important to de-
FIG. 7. Vav2/3-deficiency impairs ephrin-A1-induced angiogenesis in vivo. (A) Sponges impregnated with ephrin-A1 or IgG were subcutane-
ously implanted into the dorsal flank of Vav2/ Vav3/ mice or wild-type controls. After 7 days, mice were injected intravenously with
TRITC-dextran to visualize host blood vessels associated with sponges. Fewer surface vessels were associated with ephrin-A1-treated sponges in
/ animals relative to / controls. Scale bar, 5 mm. Arrowheads indicate surface blood vessels covering sponges. (B) Density of blood vessels
within the sponges was quantified by fluorescence intensity of rhodamine-dextran using Scion Image software. The density of fluorescent pixels
within each field (magnification, 10) was determined and compared in Vav2/ Vav3/ mice or wild-type controls. Data are a representation
of results from five independent sponges in each genotype. Statistical significance was determined by a two-tailed, paired Student’s t test.
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termine whether Vav proteins serve to directly activate Rac1
or whether Vav proteins are recruited to the activated Eph
receptor to serve an adaptor function.
Regulation of Vav GEF activation. A wealth of evidence has
demonstrated that phosphorylation of highly conserved ty-
rosine residues in the acidic domain of Vav proteins regulates
the GDP/GTP exchange activity (45). In the absence of ty-
rosine phosphorylation, the Vav acidic domain binds to the
catalytic Dbl homology domain, blocking access to Rho family
GTPases. This inhibition is released upon phosphorylation of
these tyrosine residues, resulting in activation of GDP/GTP
exchange activity. We observed constitutive phosphorylation of
Vav2 and Vav3 when they were overexpressed in COS7 cells
(data not shown). However, we were unable to detect phos-
phorylation of either endogenous Vav2 or Vav3 in primary
endothelial cells. The failure to detect tyrosine phosphoryla-
tion could be due to the relatively low abundance of Vav
proteins in these cells or to a low stoichiometry of total Vav
protein phosphorylation. Alternatively, Vav proteins may not
be significantly phosphorylated upon ephrin-A1 stimulation.
Aoki et al. observed that although Vav2/3 phosphorylation
increased upon epidermal growth factor stimulation of PC12
cells, Vav phosphorylation was not increased in response to
nerve growth factor, even though depletion of Vav2/3 signifi-
cantly inhibited NGF-induced Rac1 activation and neurite out-
growth (3).
Aside from phosphorylation-dependent activation, Vav pro-
teins may also be activated through their PH domains via a
PI3K-dependent mechanism. Vav1 was shown to be activated
in vitro by PtdIns(3,4,5)P3 (PIP3) (26) and the unphosphory-
lated Vav1 Dbl homology-PH domains can bind to Rac1 in the
presence of PIP3 (16). More recently, both Vav2 and Vav3
have been shown to be activated by PI3K-dependent translo-
cation to the membrane through their PH domains (3). We
have previously shown that ephrin-A1-induced Rac1 GTPase
activation is dependent on PI3K activity (7). In our yeast two-
hybrid screen, we identified p85 as an EphA2-interacting pro-
tein (data not shown), consistent with observations described
by Pandey et al. (36). In addition, Vav3 and p85 have been
shown to interact upon ligand stimulation both in yeast two-
hybrid assays (data not shown) and in mammalian cells (48).
Thus, it is possible that ephrin-A1 could activate Vav GEFs
through at least two mechanisms. Activated Eph receptors
could directly recruit Vav GEFs through the SH2 domain,
allowing subsequent phosphorylation and activation of Vav
proteins either directly or indirectly. In addition, through the
recruitment of p85, Eph receptors could also upregulate PIP3
levels and enhance Vav GEF activity through the PH domain
(Fig. 8).
Role of Vav GEFs in cell spreading and cytoskeletal reor-
ganization. Ephrin-A1 and EphA2 receptor have been shown
to play a critical role in the spreading and reorganization of the
cytoskeleton in both NIH 3T3 cells and primary MEFs (12).
Ephrin-A1-induced actin reorganization requires focal adhe-
sion kinase (FAK) and p130Cas (Crk-associated substrate), as
FAK/ or p130Cas/ MEFs fail to spread on an ephrin-A1-
coated surface (12). Although the mechanism by which EphA
signals to FAK and p130Cas remains unclear, it likely involves
Rho family small GTPases, which are the principle regulators
of F-actin assembly in most cell types (33, 40). Since Vav2
and/or Vav3 are involved in the ephrin-A-induced spreading
process as well, it will be important to understand the relation-
ship between Vav2/Vav3, FAK, and p130Cas. Vav proteins may
function as upstream activators, which is the case in NIH 3T3
cells where Vav3 expression induces the phosphorylation of
FAK (41). However, it is also possible that Vav activation of
Rac1 may function in a parallel signaling pathway independent
of FAK and p130Cas and act downstream of EphA receptors to
coordinately regulate actin cytoskeletal dynamics, as is the case
with Vav1 in Syk nonreceptor tyrosine kinase-mediated lamel-
lipodia formation and cell spreading (30).
Vav GEFs are required for angiogenesis. The function of
Vav proteins has been best characterized downstream of im-
mune response receptors. Targeted disruption of Vav1 leads to
severe defects in T lymphocyte functions (11) and impairs
FcR-induced degranulation and cytokine production in mast
cells (29). There are distinct defects in T- and B-cell function
in Vav1/ Vav2/ and Vav1/ Vav3/ mice, with loss of
Vav2 enhancing the B cell phenotype and loss of Vav3 enhanc-
ing the T-cell phenotype (19, 22, 43). Deletion of all Vav family
members prevents production of all mature T and B cells (22).
More recently, Vav family proteins were also shown to be
activated downstream of several growth factor receptors in
nonimmune cells (31, 48). Cowan et al. reported that Vav
family GEFs play a critical role in ephrin/Eph receptor-medi-
ated axon guidance in retinal ganglion cells during develop-
ment (10). In this study, we provide several lines of evidence
that Vav GEFs are required for ephrin-A1-induced angiogen-
esis. First, ephrin-A1 stimulation increased levels of GTP-
bound active Rac1 proteins in wild-type endothelial cells, and
this increase was absent in Vav2/ Vav3/ endothelial cells.
Second, overexpression of either Vav2 or Vav3 in primary
FIG. 8. A model for how Vav GEFs may mediate ephrin-induced
angiogenesis. Upon binding to ephrins, EphA2 receptor is tyrosine
phosphorylated. Activated EphA2 receptor recruits Vav GEFs
through the SH2 domains, resulting in subsequent activation of Vav
proteins, possibly through tyrosine phosphorylation of their acidic do-
mains. In addition, through the recruitment of the p85 subunit of PI3K,
EphA2 receptor up-regulates phospholipid PIP3 levels, which in turn
recruit and activate Vav GEFs through their PH domains. Activated
Vav GEFs subsequently increase Rac1-GTP levels and promote en-
dothelial cell migration and angiogenesis.
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bovine endothelial cells led to enhanced cell migration and
assembly in response to ephrin-A1. Conversely, loss of Vav2
and Vav3 in murine primary endothelial cells resulted in inhi-
bition of ephrin-A1-induced endothelial cell migration and
assembly. Finally, ephrin-A1-induced angiogenesis in vivo is
significantly impaired in Vav2/ Vav3/ mice.
In addition to the role of EphA2 receptor in angiogenesis,
class B Eph receptors and ephrin-Bs are involved in vascular
remodeling in both embryogenesis (2, 24, 46) and cancer (20).
We did not detect significant interaction between the EphB1
receptor and Vav3 GEF in our yeast two-hybrid screen (data
not shown). It is also unlikely that Vav2 and Vav3 proteins me-
diate signaling downstream of the EphB4 receptor, as Vav2/
Vav3/ mice are viable, whereas EphB4-deficient mice are em-
bryonic lethal due to impaired vascular remodeling.
While our data suggest that defects in Vav2/ Vav3/
cells may be due to disruption of Vav-dependent Eph signal-
ing, it is important to note that Vav proteins are activated
downstream of several growth factor receptors, some of which
have been shown to cross-talk with Eph receptors (38). Defec-
tive signaling downstream of one or several of these various
receptors could contribute to the disruption of cell migration
and assembly. With this in mind, we considered the possibility
that the defects in Vav2/ Vav3/ cell spreading, migration,
and Rac1 activation in response to ephrin-A1 stimulation
could be due to an ephrin-A-independent role for Vav proteins
in actin cytoskeletal remodeling. However, we find that the
Vav2/ Vav3/ cells effectively spread on fibronectin-coated
surfaces (Fig. 3C) and migrate toward serum in a transwell
assay (Fig. 6A), suggesting that the failure of ephrin-A1 to
induce migration and assembly in these cells is more specific to
defects in ephrin-A-induced actin cytoskeletal remodeling. We
also considered the possibility that the defects in Vav2/
Vav3/ cells could be due to changes in Eph receptor expres-
sion or activation. However, we observed no obvious differ-
ences between wild-type and Vav2/ Vav3/ cells in either
the EphA2 expression levels or phosphorylation status (Fig.
4B). Taken together, our findings support the possibility that
Vav2/Vav3 GEFs are required for regulating EphA receptor-
mediated angiogenic responses.
Although distinct functions have been attributed to different
Vav family members in certain cell types (11), our results
suggest that Vav2 and Vav3 may play overlapping roles in
regulating endothelial cell function downstream of Eph recep-
tors, as overexpression of either Vav2 or Vav3 enhances an-
giogenic responses in BPMEC. The contribution of Vav1 in
Eph-mediated angiogenic responses is, however, presently un-
clear. Although initially identified as a hematopoietic cell-spe-
cific exchange factor, Vav1 can be detected in endothelial cells
(W. Swat, personal communication), suggesting that it may
contribute to ephrin-A-induced cellular responses. Regard-
less, our findings indicate that Vav1 is not sufficient to com-
pensate for the loss of Vav2 and Vav3 in the Vav2/
Vav3/ MPMEC, establishing the critical role of Vav2/
Vav3 in ephrin-A1-induced cell migration and assembly.
In summary, we find that Vav family GEFs are required for
ephrin-A1-induced migration and assembly of endothelial
cells, a process that is dependent on Rac1 activation. These
findings suggest an important role for Vav proteins as regula-
tors of angiogenesis in vivo. It will be important to assess the
role of Vav proteins in both normal angiogenesis and in tumor
neovascularization where EphA2 receptors are known to func-
tion (7). In the future, the analysis of the Vav2/ Vav3/
mutant mice should provide an excellent model system in
which to investigate the function of Vav GEFs in tumor an-
giogenesis.
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